NICE (UK) releases final guidance for access to Harvoni, Viekirax and Daklinza hepatitis C treatments
Cinnamon Girl said
Nov 28, 2015
Following the release last month of provisional recommendations, the National Institute for Health and Care Excellence (NICE) has now published final guidance recommending Harvoni, Viekirax (with or without Exviera) and Daklinza for treatment of people with certain genotypes of hep C.
The NICE guidance documents released today will mean significantly wider access to the new non-interferon, direct acting anti-viral treatments for hepatitis C, which have shorter treatment regimes and less severe side effects for patients than previous interferon-based therapies.
The guidance means that those with hep C genotypes 1 or 4 should have treatment made available to them on the NHS within three months of guidance being issued (today, 25th November 2015).
Following the release last month of provisional recommendations, the National Institute for Health and Care Excellence (NICE) has now published final guidance recommending Harvoni, Viekirax (with or without Exviera) and Daklinza for treatment of people with certain genotypes of hep C.
The NICE guidance documents released today will mean significantly wider access to the new non-interferon, direct acting anti-viral treatments for hepatitis C, which have shorter treatment regimes and less severe side effects for patients than previous interferon-based therapies.
The guidance means that those with hep C genotypes 1 or 4 should have treatment made available to them on the NHS within three months of guidance being issued (today, 25th November 2015).
Full details...
http://www.hepctrust.org.uk/news/nov-2015/nice-releases-final-guidance-access-harvoni-viekirax-and-daklinza-hepatitis-c